Marker Therapeutics (MRKR) reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin’s Lymphoma who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback